Claims for Patent: 8,980,890

Summary for Patent: 8,980,890

Title:	Compositions and methods of treating cell proliferation disorders
Abstract:	The invention relates to compounds and methods for treating cell proliferation disorders.
Inventor(s):	David G. Hangauer, Jr.
Assignee:	Atnx Spv LLC
Application Number:	US12/950,764
Patent Claims:	1. A compound according to Formula I: or a pharmaceutically acceptable salt, tautomer, or prodrug thereof, wherein: T is a bond; Xy is CY, N, or N—O; Xz is CZ; Y is hydrogen, hydroxyl, halogen, lower (C1, C2, C3, C4, C5, or C6) alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, or O-benzyl; Xa is CRa, N, or N—O; Xb is CRb, N, or N—O; Xc is CRc, N, or N—O; Xd is CRd, N, or N—O; Xe is CRe, N, or N—O; Ra, Rb, Rc, Rd, Re, R4, R5, and R6 are, independently, hydrogen, hydroxyl, halogen, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, C1, C2, C3, C4, C5, or C6 alkyl-O-lower (C1, C2, C3, C4, C5, or C6) alkyl, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, SO2-lower (C1, C2, C3, C4, C5, or C6)alkyl, W is H, C1, C2, C3, C4, C5, or C6 alkyl, or C1, C2, C3, C4, C5, or C6 alkyl-aryl; V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2—, or —OCH2CH2CH2—; R7, R8, R9, R10, and R11 are, independently, hydrogen, hydroxyl, halogen, unsubstituted C1, C2, C3, C4, C5, or C6 alkyl, unsubstituted C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, unsubstituted C1, C2, C3, C4, C5, or C6 alkyl-OH, C1, C2, C3, C4, C5, or C6 alkyl-O—C1, C2, C3, C4, C5, or C6 alkyl, R1, R2, and R3 are independently H or C1, C2, C3, C4, C5, or C6 alkyl; n is 1, or 2; and m is 1, wherein at least one of Xa, Xb, Xc, Xd and Xe is N; provided that when Xa is N, Xe is not N. 2. The compound of claim 1, wherein Xy is CY. 3. The compound of claim 1, wherein Y is hydrogen. 4. The compound of claim 1, wherein Z is 5. The compound of claim 1, wherein Rb is C1, C2, C3, C4, C5, or C6 alkoxy. 6. The compound of claim 1, wherein Rb is wherein W is H, C1, C2, C3, C4, C5, or C6 alkyl, or C1, C2, C3, C4, C5, or C6 alkyl-aryl; and V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2—, or —OCH2CH2CH2—. 7. The compound of claim 6, wherein V is a bond. 8. The compound of claim 1, wherein Xa is N, Xb is CRb, Xc is CRc, Xd is CRd and Xe is CRe. 9. The compound of claim 1, wherein said compound is a pharmaceutically acceptable salt. 10. A composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable excipient. 11. A compound, selected from: 12. A compound according to Formula II: or a pharmaceutically acceptable salt, tautomer, or prodrug thereof, wherein: Rb, R4, R5, R8, and R10 are, independently, hydrogen, hydroxyl, halogen, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, C1, C2, C3, C4, C5, or C6 alkyl-O-lower (C1, C2, C3, C4, C5, or C6) alkyl, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, or SO2-lower (C1, C2, C3, C4, C5, or C6) alkyl, W is H, C1, C2, C3, C4, C5, or C6 alkyl, or C1, C2, C3, C4, C5, or C6 alkyl-aryl; and V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2—, or —OCH2CH2CH2—. 13. The compound of claim 1, having the formula: or a pharmaceutically acceptable salt, tautomer or prodrug thereof. 14. A composition comprising the compound according to claim 13 and at least one pharmaceutically acceptable excipient. 15. The compound of claim 1, having the formula: 16. A compound selected from: